Summary: A new study from Texas Tech University Health Sciences Center indicates that the blood-brain barrier (BBB) remains largely intact in a commonly used mouse model of Alzheimer’s disease. Using a stable tracer molecule together with highly sensitive analytical methods, the researchers found no evidence of widespread leakage across major brain regions, even in the vicinity of amyloid plaques.
These results challenge the prevailing view that Alzheimer’s disease causes a broadly leaky BBB and have important implications for how scientists design drug-delivery strategies to reach the brain. The findings also underscore the need for animal models that more closely reflect human physiology when testing Alzheimer’s therapies.
Key Facts
- Barrier Intact: No major BBB leakage was observed in the Alzheimer’s model mice studied.
- Sensitive Methods: The team used an isotope-labeled sucrose tracer, laser microdissection, and LC-MS/MS to measure tracer passage with high precision.
- Therapeutic Impact: Drug development for Alzheimer’s must account for a functioning protective barrier when planning delivery approaches.
Source: Texas Tech
Research team and background: Researchers from the Department of Pharmaceutical Sciences and the Brain Drug Discovery Center at TTUHSC’s Jerry H. Hodge School of Pharmacy (Amarillo), together with the TTUHSC Graduate School of Biomedical Sciences, led the study. Ulrich Bickel, M.D., served as principal investigator and senior author, and Ehsan Nozohouri was the lead author. Co-authors included Behnam Noorani, Dhavalkumar Patel, Yeseul Ahn and Sumaih Zoubi.
Alzheimer’s disease is characterized by progressive memory loss and cognitive decline and by hallmark features in the brain such as amyloid-beta plaques and tau tangles. For years, researchers have debated whether Alzheimer’s disrupts the blood-brain barrier—the network of tightly linked endothelial cells that control what passes from the bloodstream into the brain. The BBB normally prevents most large molecules and many smaller ones, including many drugs, from entering the central nervous system.
“The BBB excludes 99% of large molecules and over 95% of smaller ones, including many therapeutic compounds,” explained the lead researcher. “Knowing whether the BBB remains intact in Alzheimer’s is essential for designing effective treatments.”
To address this question, the team studied Tg2576 mice, a well-established transgenic model that develops amyloid plaques. They injected the animals intravenously with [¹³C₁₂]sucrose, a stable isotope-labeled tracer that ordinarily crosses the BBB very poorly. Thirty minutes after injection, researchers collected plasma and dissected brain regions using laser microdissection to isolate specific tissue areas. Tracer concentrations were measured with liquid chromatography–tandem mass spectrometry (LC-MS/MS), a method capable of detecting minute amounts of tracer in tissue.
Key findings from the study were:
- No widespread leakage: Brain sucrose levels were extremely low in both Tg2576 (Alzheimer’s model) and wild-type control mice at both younger and older ages, indicating limited paracellular passage across the BBB.
- Regional consistency: Core regions involved in memory and cognition—the hippocampus, cortex and cerebellum—showed similar tracer uptake and clearance in both groups.
- Tight junction preservation: Immunohistochemical analysis of key tight junction proteins (claudin-5, occludin and ZO-1) showed no major loss or redistribution across the examined regions, suggesting the structural integrity of the BBB remains largely intact.
High-resolution imaging revealed small, localized disruptions to tight junctions adjacent to some amyloid plaques, but targeted microdissection and LC-MS/MS analysis did not detect increased tracer levels in those plaque-associated areas. In other words, minor structural changes close to amyloid deposits did not translate into measurable increases in BBB permeability at the tissue level in this model.
“Our results challenge the assumption that Alzheimer’s disease necessarily involves widespread BBB leakiness,” the lead author said. “If the barrier remains functional, drug developers must design delivery strategies that can cross a largely intact protective shield rather than relying on generalized barrier breakdown.”
The study also notes limitations and next steps. Tg2576 mice are a valuable tool but may not fully recapitulate human disease, so the authors stress the importance of validating results across other models and in human tissue where possible. The team plans to examine whether treatments—such as rodent-equivalent monoclonal antibodies—or pathological events like microhemorrhages or localized swelling might produce BBB changes not detected here.
Ultimately, the investigators emphasize that accurately assessing BBB integrity requires multiple complementary methods. Improved understanding of BBB status in Alzheimer’s will better inform dosing, formulation and delivery technologies for therapeutics aimed at slowing cognitive decline.
Key Questions Answered
A: In the Tg2576 mouse model used in this study, researchers did not find evidence of widespread BBB leakage, a finding that challenges prior assumptions.
A: The team injected an isotope-labeled sucrose tracer and used laser microdissection and LC-MS/MS to precisely measure tracer distribution across defined brain regions.
A: If the BBB remains functional in patients as it does in this model, drug delivery strategies must overcome an intact barrier, which has implications for the design and selection of therapeutic agents.
About this Alzheimer’s disease and neurology research news
Author: Suzanna Cisneros
Source: Texas Tech
Contact: Suzanna Cisneros – Texas Tech
Image: The image is credited to Neuroscience News
Original Research: Open access. “Assessing blood-brain barrier (BBB) integrity in an Alzheimer’s disease mouse model: is the BBB globally or locally disrupted?” by Ulrich Bickel et al., published in Fluids and Barriers of the CNS. DOI: 10.1186/s12987-025-00685-2
Abstract
Assessing blood-brain barrier (BBB) integrity in an Alzheimer’s disease mouse model: is the BBB globally or locally disrupted?
Alzheimer’s disease (AD), distinguished by amyloid-beta plaques and tau tangles, often co-occurs with cerebral amyloid angiopathy (CAA), which has been proposed to compromise BBB integrity. The extent and nature of any BBB disruption in AD, however, are not fully resolved. This study evaluated unidirectional paracellular transport from blood to brain in Tg2576 AD mice after intravenous injection of the stable isotope-labeled marker [¹³C₁₂]sucrose.
Pharmacokinetic analysis of plasma and brain concentrations 30 minutes after injection revealed minimal sucrose passage across the BBB in both AD and wild-type mice, indicating preserved barrier function despite amyloid deposition. Regional clearance rates in hippocampus, cortex and cerebellum were comparable between groups, with only the olfactory bulbs showing increased uptake. Immunohistochemical assessment of tight junction proteins (claudin-5, occludin, ZO-1) demonstrated no significant differences between AD and control animals.
High-resolution imaging identified minor tight junction disruptions near some amyloid plaques, but targeted laser microdissection and LC-MS/MS analyses found no elevated tracer concentrations in vascular Aβ–deposition zones. These results suggest that localized structural changes do not produce substantial increases in BBB permeability in this model. The study challenges the assumption of widespread BBB leakiness in the Tg2576 AD model and highlights the importance of multi-method approaches for assessing BBB integrity and optimizing drug delivery strategies for Alzheimer’s disease.